and ritonavir had little therapeutic benefit in patients
with COVID-19, but appeared more effective when used
in combination with other drugs, including ribavirin and
interferon beta-1b'**'“. The Randomized Evaluation of

COVID-19 Therapy (RECOVERY) trial, a national clin-
ical trial programme in the UK, has stopped treatment
with lopinavir and ritonavir as no significant beneficial
effect was observed in a randomized trial established in

March 2020 with a total of 1,596 patients'*’. Nevertheless,
